Role of proteomics in the investigation of pulmonary fibrosis

Expert Review of Proteomics

Volumn 4, Issue 3, 2007, Pages 379-388

  Govender, Praveen ^a   Baugh, John A ^b   Pennington, Stephen R ^b   Dunn, Michael J ^b   Donnelly, Seamas C ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

BAL; Bronchoalveolar lavage; Bronchoscopy; Lung; Proteomics; Pulmonary fibrosis

Indexed keywords

BIOLOGICAL MARKER;

BRONCHOSCOPY; CLINICAL ASSESSMENT TOOL; DIAGNOSTIC PROCEDURE; DISEASE COURSE; HUMAN; LUNG FIBROSIS; LUNG LAVAGE; MASS SPECTROMETRY; MORBIDITY; MORTALITY; PROTEOMICS; REVIEW; STATISTICAL SIGNIFICANCE; TARGET ORGAN;

BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MASS SPECTROMETRY; PROTEOME; PROTEOMICS; PULMONARY FIBROSIS;

EID: 34249990315     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.4.3.379     Document Type: Review

References (71)

1. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction. Thorax 54(Suppl.1), S1-S14 (1999).
2. Flaherty KR, Mumford JA, Murray S et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 168(5), 543-548 (2003).
3. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 168(5), 538-542 (2003).
4. Lama VN, Flaherty KR, Toews GB et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 168(9), 1084-1090 (2003).
5. Thannickal VJ, Toews GB, White ES, Lynch JP III, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu. Rev. Med. 55, 395-417 (2004). • Comprehensive review on the current concept of the pathogenesis of pulmonary fibrosis.
6. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am. J. Respir. Crit. Care Med. 165(2), 277-304 (2002). • The current consensus classification system of pulmonary fibrosis.
7. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med. 157(4 Pt 1), 1301-1315 (1998).
8. Raghu G, Brown KK, Bradford WZ et al. A placebo-controlled trial of interferon γ-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 350(2), 125-133 (2004).
9. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med. 159(4 Pt 1), 1061-1069 (1999).
10. Azuma A, Nukiwa T, Tsuboi E et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 171(9), 1040-1047 (2005).
11. Demedts M, Behr J, Buhl R et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 353(21), 2229-2242 (2005).
12. Robbins SL, Cotran RS. Chapter 16: The Lung. In: Robbins Pathologic Basis of Disease. Kumar V, Collins T (Eds). Saunders WB Co Ltd., PA, USA 726-738 (1999).
13. Edell ES. Future therapeutic procedures. Chest Surg. Clin. N. Am. 6(2), 381-395 (1996).
14. Winterbauer RH, Lammert J, Selland M, Wu R, Corley D, Springmeyer SC. Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 104(2), 352-361 (1993).
15. Costabel U. Sensitivity and specificity of BAL findings in sarcoidosis. Sarcoidosis 9(Suppl.1), S211-S214 (1992).
16. Lenz AG, Meyer B, Weber H, Maier K. Two-dimensional electrophoresis of dog bronchoalveolar lavage fluid proteins. Electrophoresis 11(6), 510-513 (1990).
17. Lindahl M, Stahlbom B, Svartz J, Tagesson C. Protein patterns of human nasal and bronchoalveolar lavage fluids analyzed with two-dimensional gel electrophoresis. Electrophoresis 19(18), 3222-3229 (1998).
18. Wattiez R, Hermans C, Cruyt C, Bernard A, Falmagne P. Human bronchoalveolar lavage fluid protein two-dimensional database: study of interstitial lung diseases. Electrophoresis 21(13), 2703-2712 (2000).
19. Bell DY, Hook GE. Pulmonary alveolar proteinosis: analysis of airway and alveolar proteins. Am. Rev. Respir. Dis. 119(6), 979-990 (1979).
20. Lenz AG, Meyer B, Costabel U, Maier K. Bronchoalveolar lavage fluid proteins in human lung disease: analysis by two-dimensional electrophoresis. Electrophoresis 14(3), 242-244 (1993).
21. Wattiez R, Hermans C, Bernard A, Lesur O, Falmagne P. Human bronchoalveolar lavage fluid: two-dimensional gel electrophoresis, amino acid microsequencing and identification of major proteins. Electrophoresis 20(7), 1634-1645 (1999).
22. Noel-Georis I, Bernard A, Falmagne P, Wattiez R. Proteomics as the tool to search for lung disease markers in bronchoalveolar lavage. Dis. Markers 17(4), 271-284 (2001).
23. Noel-Georis I, Bernard A, Falmagne P, Wattiez R. Database of bronchoalveolar lavage fluid proteins. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 771(1-2), 221-236 (2002). • Database of bronchoalveolar lavage fluid proteins.
24. Wattiez R, Falmagne P. Proteomics of bronchoalveolar lavage fluid. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 815(1-2), 169-178 (2005).
25. Magi B, Bini L, Perari MG et al. Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study. Electrophoresis 23(19), 3434-3444 (2002).
26. Rottoli P, Magi B, Cianti R et al. Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 5(10), 2612-2618 (2005).
27. Rottoli P, Magi B, Perari MG et al. Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 5(5), 1423-1430 (2005).
28. Sabounchi-Schutt F, Astrom J, Eklund A, Grunewald J, Bjellqvist B. Detection and identification of human bronchoalveolar lavage proteins using narrow-range immobilized pH gradient DryStrip and the paper bridge sample application method. Electrophoresis 22(9), 1851-1860 (2001).
29. Sabounchi-Schutt F, Astrom J, Hellman U, Eklund A, Grunewald J. Changes in bronchoalveolar lavage fluid proteins in sarcoidosis: a proteomics approach. Eur. Respir. J. 21(3), 414-420 (2003).
30. Kriegova E, Melle C, Kolek V et al. Protein profiles of bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 173(10), 1145-1154 (2006).
31. Malmström J, Westergren-Thorsson G, Marko-Varga G. A proteomic approach to mimic fibrosis disease evolvement by an in vitro cell line. Electrophoresis 22(9), 1776-1784 (2001).
32. Malmström J, Larsen K, Malmström L et al. Proteome annotations and identifications of the human pulmonary fibroblast. J. Proteome Res. 3(3), 525-537 (2004).
33. Malmstrom J, Larsen K, Malmstrom L et al. Nanocapillary liquid chromatography interfaced to tandem matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry: mapping the nuclear proteome of human fibroblasts. Electrophoresis 24(21), 3806-3814 (2003).
34. Sabounchi-Schutt F, Mikko M, Eklund A, Grunewald J, Astrom J. Serum protein pattern in sarcoidosis analysed by a proteomics approach. Sarcoidosis Vasc. Diffuse Lung Dis. 21(3), 182-190 (2004).
35. Song Z, Marzilli L, Greenlee BM et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J. Exp. Med. 201(5), 755-767 (2005).
36. Jordana M, Dolovich M, Newhouse M. Lung epithelial permeability in sarcoidosis. Sarcoidosis 4(2), 116-121 (1987).
37. Hirsch J, Hansen KC, Burlingame AL, Matthay MA. Proteomics: current techniques and potential applications to lung disease. Am. J. Physiol. Lung Cell Mol. Physiol. 287(1), L1-L23 (2004). •• Excellent comprehensive review of proteomics technologies and a review of the literature in all areas of pulmonary disease.
38. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1(11), 845-867 (2002).
39. Boggs SE. Protein profiling in respiratory disease: techniques and impact. Expert Rev. Proteomics 1(1), 29-36 (2004). • SELDI and applications to pulmonary disease.
40. Malmstrom J, Larsen K, Hansson L et al. Proteoglycan and proteome profiling of central human pulmonary fibrotic tissue utilizing miniaturized sample preparation: a feasibility study. Proteomics 2(4), 394-404 (2002).
41. Larsen K, Macleod D, Nihlberg K et al. Specific haptoglobin expression in bronchoalveolar lavage during differentiation of circulating fibroblast progenitor cells in mild asthma. J. Proteome Res. 5(6), 1479-1483 (2006).
42. Larsen K, Tufvesson E, Malmstrom J et al. Presence of activated mobile fibroblasts in bronchoalveolar lavage from patients with mild asthma. Am. J. Respir. Crit. Care Med. 170(10), 1049-1056 (2004).
43. Larsen K, Malmstrom J, Wildt M et al. Functional and phenotypical comparison of myofibroblasts derived from biopsies and bronchoalveolar lavage in mild asthma and scleroderma. Respir. Res. 7, 11 (2006).
44. Scheja A, Larsen K, Todorova L et al. BAL fluid derived fibroblasts differ from biopsy derived fibroblasts in systemic sclerosis. Eur. Respir. J. 29(3) 446-452 (2006).
45. Nihlberg K, Larsen K, Hultgardh-Nilsson A, Malmstrom A, Bjermer L, Westergren-Thorsson G. Tissue fibrocytes in patients with mild asthma: a possible link to thickness of reticular basement membrane? Respir. Res. 7, 50 (2006).
46. Wasinger VC, Cordwell SJ, Cerpa-Poljak A et al. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 16(7), 1090-1094 (1995).
47. Wilkins MR, Sanchez JC, Gooley AA et al. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol. Genet. Eng. Rev. 13, 19-50 (1996).
48. Wu WW, Wang G, Baek SJ, Shen RF. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, Using 2D Gel- or LC-MALDI TOF/TOF. J. Proteome Res. 5(3), 651-658 (2006).
49. Plymoth A, Lofdahl CG, Ekberg-Jansson A et al. Human bronchoalveolar lavage: biofluid analysis with special emphasis on sample preparation. Proteomics 3(6), 962-972 (2003). • Examination of different sample preparation methods of bronchoalveolar lavage fluid.
50. Bowler RP, Duda B, Chan ED et al. Proteomic analysis of pulmonary edema fluid and plasma in patients with acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 286(6), L1095-L1104 (2004).
51. Magi B, Bargagli E, Bini L, Rottoli P. Proteome analysis of bronchoalveolar lavage in lung diseases. Proteomics 6(23), 6354-6369 (2006).
52. Westbrook JA, Wheeler JX, Wait R, Welson SY, Dunn MJ. The human heart proteome: Two-dimensional maps using narrow-range immobilised pH gradients. Electrophoresis 27(8), 1547-1555 (2006).
53. McGregor E, Dunn MJ. Proteomics of the heart: unraveling disease. Circ. Res. 98(3), 309-321 (2006).
54. Patton WF. Detection technologies in proteome analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 771(1-2), 3-31 (2002).
55. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18(11), 2071-2077 (1997).
56. Lilley KS, Friedman DB. All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev. Proteomics 1(4), 401-409 (2004). • Excellent review on DIGE.
57. Greenlee KJ, Corry DB, Engler DA et al. Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation. J. Immunol. 177(10), 7312-7321 (2006).
58. Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 4(12), 3665-3685 (2004). •• State of the art manuscript on 2D gel electrophoresis and issues in gel-based proteomics.
59. Ge Y, Rajkumar L, Guzman RC, Nandi S, Patton WF, Agnew BJ. Multiplexed fluorescence detection of phosphorylation, glycosylation, and total protein in the proteomic analysis of breast cancer refractoriness. Proteomics 4(11), 3464-3467 (2004).
60. Wu J, Kobayashi M, Sousa EA et al. Differential proteomic analysis of bronchoalveolar lavage fluid in asthmatics following segmental antigen challenge. Mol. Cell. Proteomics 4(9), 1251-1264 (2005).
61. Tang HY, Ali-Khan N, Echan LA, Levenkova N, Rux JJ, Speicher DW. A novel four-dimensional strategy combining protein and peptide separation methods enables detection of lowabundance proteins in human plasma and serum proteomes. Proteomics 5(13), 3329-3342 (2005).
62. Michel PE, Crettaz D, Morier P et al. Proteome analysis of human plasma and amniotic fluid by off-gel isoelectric focusing followed by nano-LC-MS/MS. Electrophoresis 27(5-6), 1169-1181 (2006).
63. Wu L, Han DK. Overcoming the dynamic range problem in mass spectrometry-based shotgun proteomics. Expert Rev. Proteomics 3(6), 611-619 (2006).
64. Schnapp LM, Donohoe S, Chen J et al. Mining the acute respiratory distress syndrome proteome: identification of the insulin-like growth factor (IGF)/IGF-binding protein-3 pathway in acute lung injury. Am. J. Pathol. 169(1), 86-95 (2006).
65. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17(10), 994-999 (1999).
66. Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3(12), 1154-1169 (2004).
67. Julka S, Regnier FE. Recent advancements in differential proteomics based on stable isotope coding. Brief. Funct. Genomic. Proteomic. 4(2), 158-177 (2005).
68. Candiano G, Bruschi M, Pedemonte N et al. Proteomic analysis of the airway surface liquid: modulation by proinflammatory cytokines. Am. J. Physiol. Lung Cell Mol. Physiol. 292(1), L185-L198 (2007).
69. Cahill DJ. Protein and antibody arrays and their medical applications. J. Immunol. Methods 250(1-2), 81-91 (2001).
70. Haab BB. Applications of antibody array platforms. Curr. Opin. Biotechnol. 17(4), 415-421 (2006).
71. Pulmonary Fibrosis Foundation www.pulmonaryfibrosis.org